CMBA
PTCT icon

C.M. Bidwell & Associates’s PTC Therapeutics PTCT Stock Holding History

C.M. Bidwell & Associates’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.22K Buy
+64
New +$4.62K ﹤0.01% 338

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

C.M. Bidwell & Associates's PTCT Position: Q2 2026 in Review

C.M. Bidwell & Associates opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 64 shares worth $5.22K. The stake represents ﹤0.01% of the portfolio and ranks #338 among its holdings.

382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • C.M. Bidwell & Associates held 64 shares of PTC Therapeutics worth $5.22K as of Q2 2026.
  • PTC Therapeutics was a new C.M. Bidwell & Associates position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #338 holding.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.